Mannkind Corporation

Seattle Children's Hospital

Smith + Nephew

Seattle Children's Hospital Dba Seattle Children's Research Institute

Peter Richardson

Robert A Baughman

Anders Hasager Boss

Richard Petrucci

Donald Costello

Elizabeth Potocka

Mark T Marino

Charles Smith

Alfred Mann

Campbell Howard

Thomas N Hansen

Jay C Zignego

Robert M DiBlasi

Andrea Leone-Bay

Grayson Walker Stowell

Marshall L Grant

Fraser Harvie

Adam Graham James

Enda Kenny

James William Huckle

Scott Daniels

Stephanie Greene

Anthony Smithson

Per Hellstrom

Thomas N Jansen

Robert M Diblasi

Charles V Smith

Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.

Method of treating diabetes type 2 by administering ultrarapid acting insulin

A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.

Inhalable dry powder pharmaceutical composition

Use of ultrarapid acting insulin

A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with Type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.

Method for treating hyperglycemia with GLP-1

Method for treating hyperglycemia

A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient. The method comprises administering a formulation by pulmonary inhalation comprising a diketopiperazine and a glucagon-like peptide (GLP-1), analog, ROSE-010.

Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome

It has been discovered that high amplitude, low frequency, broadband spectrum pressure oscillations of sufficient time duration can help stabilize lung volumes and improve gas exchange in a patient receiving ventilation assistance by helping to recruit and stabilize alveoli. A novel device is presented which can produce pressure oscillations having high amplitudes, a low broad-band frequency spectrum and long time duration. Additionally, the device can maintain a patient's mean airway pressure at one or more controlled levels. The device can control the oscillatory amplitude, frequency range and composition, time duration, and mean airway pressure levels by adjusting certain device parameters, such as the angle and depth of the device in a fluid. A device and mechanical system for remotely adjusting and measuring the angle of the device in a fluid are also disclosed. Furthermore, a device and system are disclosed that can deliver pressure oscillations having high amplitudes, a low broad-band frequency spectrum, long time duration, and multiple mean airway inspiratory and expiratory pressure levels. The device and system also provide means for controlling respiration timing in a patient, including: breaths per minute, inspiratory time, and the ratio of inspiratory to expiratory time.

Broad-band, low frequency, high-amplitude, long time duration, oscillating airway pressure breathing apparatus and method utilizing bubbles

A method for preventing or reducing adverse effects such as profuse sweating, nausea and vomiting, which normally are associated with subcutaneous and intravenous administration of glucagon-like peptide 1 (GLP-1) therapy is provided. In particular, the method comprises the rapid administration of a GLP-1 formulation into the pulmonary circulation such as by inhalation, directly into pulmonary alveolar capillaries using a dry powder drug delivery system.

Method of preventing adverse effects by GLP-1

A method of introducing a physiologically-active agent into the circulatory system of a mammal is disclosed herein. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent being administered to a patient in need of treatment. In particular, the drug delivery system is designed for pulmonary drug delivery such as by inhalation, for delivery of the active agents such as proteins and peptides to the pulmonary circulation in a therapeutically effective manner avoiding degradation of the active agents in peripheral and vascular tissue before reaching the target site.

Delivery of active agents

Method of treating diabetes type 2 by metformin and an ultrarapid acting insulin

Growing community of inventors

Ringoes, NJ, United States of America

Peter Richardson